Regeneron Pharmaceuticals recently published results from LUMINA-1, a clinical trial that investigated the safety and effect of garetosmab (also named REGN2477) in people with FOP. Results from the Phase 2 trial showed that garetosmab achieved an approximately 90% reduction in new heterotopic bone formation as measured by two imaging techniques. The majority of adverse events were judged to be mild to moderate in severity. You can read more about the LUMINA-1 clinical trial on clinicaltrials.gov or about the results with garetosmab from Regeneron’s press release.
As noted in the press release, Regeneron plans to review the clinical data results with regulators to determine next steps for developing this investigational therapy.